Related coverage linked through entity extraction aliases.
Aug 24, 2026
MD Anderson researchers developed GT19630, a first-in-class dual-degrader targeting MYC and GSPT1, showing potent preclinical activity in blood cancers including treatment-resistant and TP53-mutated disease. The drug also restored venetoclax sensitivity in resistant AML models.
Aug 02, 2026
Recent studies show microbiome modulation boosts chemotherapy accumulation, peptide-based mRNA vaccines shrink neuroblastoma tumors by 70%, and engineered LNPs enhance lymph node delivery while cutting side effects.
Jun 30, 2026
Two phase 3 trials tested radiation approaches for brain metastases. Tile-based brachytherapy cut 1-year recurrence to 1.3% and improved median overall survival. Stereotactic radiation reduced symptom burden versus whole brain radiation.
Jul 17, 2026
New CAR T-cell data show 100% MRD negativity in high-risk smoldering multiple myeloma, a novel CAR T approach for AML, and a new T-cell pathway, while a case report warns of a rare therapy-related complication.
Jul 15, 2026
Researchers at MD Anderson developed an extracellular vesicle-based platform that delivers full-length DMD mRNA, restoring dystrophin production and improving muscle function in preclinical Duchenne muscular dystrophy models. The study, published in Nature Biomedical Engineering, showed reduced side effects compared with viral gene therapies.
Jul 07, 2026
LIXTE is pivoting to AI energy infrastructure for data centers; shares slipped 5.78% to $5.89. A Denham Capital founder joined the board; a partner will be sought for its oncology operations.
Jul 30, 2026
A study in Cancer Cell reveals that immature NK cells in donor cord blood can sabotage CAR NK cell therapy through trogocytosis, causing fratricide. Removing these cells before manufacturing improves antitumor activity in preclinical models, offering a strategy for more consistent off-the-shelf therapies.
Apr 28, 2026
Compass Therapeutics reported mixed Phase 2/3 data for tovecimig in biliary tract cancer and plans to meet with the FDA for a BLA discussion. The study met its primary ORR endpoint (17% vs 5%), while PFS and OS data are due late this quarter.
Feb 18, 2026
Researchers at The University of Texas MD Anderson Cancer Center developed a computational approach using tumor-specific total mRNA expression (TmS) that outperformed current methods for predicting chemotherapy response in triple-negative breast cancer patients.
